UAB MedCast

Cystic Fibrosis: New CF Research & Clinical Trials

George Solomon, MD - Speaker Bio
Dr. Solomon's clinical interest centers on the care of CF and non-CF bronchiectasis patients and the pursuit of continued inpatient medicine care of these patients in the acute care setting. 

Learn more about George Solomon, MD 

Release Date: May 9, 2022
Expiration Date: May 8, 2025

Disclosure Information:

Ronan O’Beirne, EdD, MBA
Director, UAB Continuing Medical Education
Katelyn Hiden
Physician Marketing Manager, UAB Health System

The planners have no relevant financial relationships with ineligible companies to disclose.

George Solomon, MD
Associate Professor, Critical Care Medicine & Pulmonology

Dr. Solomon has disclosed the following financial relationships with ineligible companies:

Grants/Research Support/Grants Pending - Vertex, Insmed, Boeringer-Ingelheim, Electromed, CFF, NIH, ATS
Consulting Fee - Electromed, Insmed
Honorarium - Vertex
Board Membership - Electromed, Spark Healthcare
Payment for Development of Educational Presentations - Spark Healthcare
Payment for Lectures, Including Service on Speakers Bureaus - Insmed, Electromed

All relevant financial relationships have been mitigated. Dr. Solomon does not intend to discuss the off-label use of a product. No other speakers, planners or content reviewers, have any relevant financial relationships with ineligible companies to disclose.

There is no commercial support for this activity.
  • Topic Info:Although most cystic fibrosis (CF) patients respond to new drug combinations which activate the proteins commonly affected by the disease, around 15% of patients are still without a treatment option. George Solomon, MD, discusses how UAB’s participation in the international “Path to a Cure” initiative will expand treatment options for all CF patients. He summarizes the three prongs of the path: developing a wider range of protein modulators, finding safe and ethical ways to administer genetic therapies, and ultimately finding a universal cure for CF. But what can we do now for CF patients with less common mutations? Learn more about how the UAB Medicine Cystic Fibrosis Program gives patients with tough-to-treat protein mutations access to emerging therapies through clinical trials.